Bioheart, Inc. Share Price OTC Bulletin Board
Equities
US09062F2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Sales 2021 | 201K 16.73M | Sales 2022 | 82.05K 6.84M | Capitalization | 3.05M 254M |
---|---|---|---|---|---|
Net income 2021 | -3M -250M | Net income 2022 | -2M -167M | EV / Sales 2021 | 59.5 x |
Net Debt 2021 | 8.93M 744M | Net Debt 2022 | 10.08M 840M | EV / Sales 2022 | 160 x |
P/E ratio 2021 |
-0.84
x | P/E ratio 2022 |
-0.99
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.05% |
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 01/03/01 |
Mark Borman
CHM | Chairman | 69 | 01/09/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 05/17/05 |
Director/Board Member | 100 | 01/03/01 | |
Mark Borman
CHM | Chairman | 69 | 01/09/01 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |